What’s Super Intelligence? An Explainer
A detailed explanation of what exactly Super Intelligence is, plus policy direction from CMS on the adoption of AI in healthcare and how that fits into Medicare and Medicaid moving forward.
.png)
Subscribe
Get the latest news and tips directly in your inbox by subscribing to our monthly newsletter
If you’ve had an eye on the news, you’ve probably heard a new phrase pop up in recent weeks: superintelligence. What is it? What does it mean? We’re here to clarify for you.
Is Super Intelligence just AI?
Yes.
Now that that’s out of the way, are there any interesting developments on that front?
The Centers for Medicare and Medicaid Services (CMS) just published guidance on A Clinical Super Intelligence Roadmap: Better Answers, Faster Care, and Lower Costs that outlined an acceleration of AI in healthcare.
The paper outlines the promise AI offers in healthcare—a companion tool to clinicians' expertise that can help manage the cumbersome healthcare process for both clinicians and patients—provided it meets two key criteria: improving access and driving affordability.
CMS goes on to outline some of what it calls its “core guiding principles” for clinical AI, quoted below:
- Safe and Reliable: Hold clinical SI to a “better than today” standard for safety, effectiveness, access, and outcomes, while recognizing that the current system is already imperfect.
- Earned and Progressive Adoption: Build trust through staged deployment, transparent evidence, appropriate human oversight, and continuous real-world monitoring.
- Personal Ownership: Patients should control their health data, consent to its use in SI, and remain empowered to steer their own health care decisions.
- Affordability Driver: Prioritize technologies and payment models that lower total health care costs while expanding access to high-quality care and improved health outcomes.
- Permanent Market Access: Create durable pathways for innovators that reflect the speed and potential of rapidly evolving technology.
To achieve their ultimate goal of integrating AI into healthcare in a way that’s both safe and effective and leaves clinicians in control and comfortable with AI’s deployment, CMS is looking at a few measured steps on the path forward.
First, it outlines that the goal shouldn’t be to immediately adopt clinical AI everywhere, but to start with lower-risk cases and learn from those implementations before allowing AI agents greater autonomy.
Second, adoption has to be paired with building trust. CMS notes that there needs to be transparency about what clinical SI can and can’t do and its performance in actual clinical settings. It needs to be used in a way that protects a patient’s choice, consent, and control over health decisions and helps them become more informed and engaged patients.
CMS believes that broader adoption also requires a strong data foundation — one that allows for patients, providers, and payers to have access to all of the information they need, when they need it. CMS is calling for:
- Expanded patient access to their own records and provider-to-provider data exchange,
- Stronger real-world, real-time evidence systems to track the performance of AI systems, and
- Secure data pathways for developers building validated, patient-centered tools.
Greater use of AI is going to require a more cohesive set of rules, per CMS, which is why they’re looking to match FDA regulation to the respective level or risk and activity, use real-world monitoring to seek continued improvement and accountability for AI models, work with state AI “sandboxes” around needed state regulations, and explore ways that innovators can introduce lower-risk treatments through AI.
Lastly, their road forward with AI/SI demands that CMS put their money where their mouth is, which means paying for solutions that meet their broader goals of better outcomes and lower costs. To those ends, CMS is planning to:
- Expand payments for outcomes-based, AI-enabled support that helps with chronic disease management, prevention, screening, and lifestyle coaching,
- Offer options centered around clinical AI for accountable primary care and total-cost-of-care payment structures
- Collaborate with states to test clinical AI payment models that improve access to care
- Creating outcomes-based payment approaches in Medicare that could encourage AI-centered approaches on the clinical side, and
- Fostering AI-led clinical offerings within the ACA Marketplace and for Medicare Advantage plans.
The full paper is an interesting read for getting a sense of CMS’s stated aims for AI moving forward, which we may or may not see implemented over the coming years. I’ll leave you with this passage on what CMS will definitively not do, at least at the time of publication:
“Credibility comes from limits as much as from ambition. This roadmap does not mandate SI adoption. It complements clinical judgment where the stakes are highest to foster highest-quality outcomes. It does not authorize autonomy that has not cleared the “better than today” bar for its risk tier. It does not create a new agency or duplicate an existing regulator. And it does not hold SI to a standard of perfection: it will not wait for flawless evidence to open pathways, but it will require evidence to keep them open.”
Speaking of AI, be sure to check out meetaera.com to learn more about how Aera is doing more than creating a roadmap; it’s built to change the way rehab therapy practices work in 2027.


.png)


